» Articles » PMID: 31914062

Hypoglycemic Risk Exposures in Relation to Low Serum Glucose Values in Ambulatory Patients

Overview
Specialty General Medicine
Date 2020 Jan 9
PMID 31914062
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to correlate hypoglycemic risk exposures (HREs) with low blood glucose value (BGV) in ambulatory patients to inform selection of a glucose critical action value (CAV).This was a retrospective study of ambulatory patients with at least 1 serum glucose ≤70 mg/dL obtained at 2 laboratories within the Johns Hopkins Health System over 3.8 years. Multivariable logistic regression was used to evaluate association of BGV cut-offs of <60, <54, <50, and <45 mg/dL with HREs. HREs were classified as "high hypoglycemic risk" (HHR), "moderate hypoglycemic risk" (MHR), "low hypoglycemic risk" (LHR), and "no hypoglycemic risk" (NHR).A total of 5404 patient samples of BG ≤70 mg/dL were analyzed, of which 30.3%, 23.2%, 28.5%, 18.0% occurred in NHR, LHR, MHR, and HHR groups, respectively. An inverse relationship was noted between BGV cut-offs and HHR, but no association was observed for LHR or MHR. After adjusting for age, sex, and race, there was an inverse association between BG thresholds and the odds of HHR. For classification of HHR, BGV cut-offs of <60, <54, <50, and <45 mg/dL correctly classified 71.2%, 69.8%, 68.8%, and 67.2% of BG samples, achieved false-positive rates of 13.6%, 4.7%, 1.7%, and 0.5% and positive likelihood ratios of 3.3, 6.0, 11.2, and 23.4, respectively.Nearly 70% of low BGVs occurred in patients with at least 1 HRE, but only ∼20% occurred in HHR patients. Given their high positive likelihood ratios, BGVs <54 or <50 mg/dL are reasonable candidates for CAVs that would allow sufficient clinician response time while minimizing false-positive alerts.

Citing Articles

Provider Response to Critical Action Values for Hypoglycemia in the Ambulatory Setting: a Retrospective Cohort Study.

Ashok A, Abusamaan M, Parker P, Pilla S, Mathioudakis N J Gen Intern Med. 2020; 36(5):1244-1249.

PMID: 32935316 PMC: 8131438. DOI: 10.1007/s11606-020-06225-y.

References
1.
. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2016; 40(1):155-157. DOI: 10.2337/dc16-2215. View

2.
Bruderer S, Bodmer M, Jick S, Bader G, Schlienger R, Meier C . Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis. Diabetes Obes Metab. 2014; 16(9):801-11. DOI: 10.1111/dom.12282. View

3.
Carey M, Gospin R, Goyal A, Tomuta N, Sandu O, Mbanya A . Opioid Receptor Activation Impairs Hypoglycemic Counterregulation in Humans. Diabetes. 2017; 66(11):2764-2773. PMC: 5652610. DOI: 10.2337/db16-1478. View

4.
Cryer P, Axelrod L, Grossman A, Heller S, Montori V, Seaquist E . Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 94(3):709-28. DOI: 10.1210/jc.2008-1410. View

5.
McGee S . Simplifying likelihood ratios. J Gen Intern Med. 2002; 17(8):646-9. PMC: 1495095. DOI: 10.1046/j.1525-1497.2002.10750.x. View